NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have been given an average rating of “Moderate Buy” by the twelve research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $48.00.

A number of research analysts have issued reports on NAMS shares. Wall Street Zen lowered shares of NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Leerink Partners restated an “outperform” rating and set a $55.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, January 6th. Stifel Nicolaus increased their target price on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. Finally, Royal Bank Of Canada increased their target price on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 21st.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, Director Louis G. Lange sold 44,619 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $30.42, for a total transaction of $1,357,309.98. Following the completion of the sale, the director owned 10,360 shares of the company’s stock, valued at approximately $315,151.20. This represents a 81.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael H. Davidson sold 443,707 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $33.25, for a total transaction of $14,753,257.75. Following the sale, the chief executive officer directly owned 174,144 shares of the company’s stock, valued at approximately $5,790,288. This trade represents a 71.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 1,313,286 shares of company stock worth $42,963,764. 20.84% of the stock is currently owned by company insiders.

Institutional Trading of NewAmsterdam Pharma

A number of institutional investors and hedge funds have recently made changes to their positions in NAMS. Farther Finance Advisors LLC lifted its holdings in shares of NewAmsterdam Pharma by 4,425.0% during the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after acquiring an additional 708 shares during the period. Mather Group LLC. bought a new stake in shares of NewAmsterdam Pharma during the 3rd quarter worth approximately $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of NewAmsterdam Pharma during the 3rd quarter worth approximately $30,000. Wells Fargo & Company MN lifted its holdings in shares of NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after acquiring an additional 300 shares during the period. Finally, Navalign LLC bought a new stake in shares of NewAmsterdam Pharma during the 4th quarter worth approximately $46,000. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Stock Performance

Shares of NAMS opened at $34.44 on Wednesday. NewAmsterdam Pharma has a 52 week low of $15.70 and a 52 week high of $42.00. The firm has a market cap of $3.96 billion, a P/E ratio of -19.91 and a beta of 0.13. The firm’s 50-day simple moving average is $32.72 and its 200 day simple moving average is $34.45.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The company had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.92 million. As a group, equities analysts forecast that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.